Design of a Randomized Placebo Controlled Trial of High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation

Delirium is a highly prevalent neuropsychiatric condition with major health consequences in the medically ill [1,2]. Patients undergoing hematopoietic stem cell transplantation (HSCT) are at high risk for delirium because they often present with advanced disease and have completed one or more courses of chemotherapy. Patients receiving allogeneic transplantation may be at even higher risk due to the greater toxicity of their treatment, longer hospitalization, and higher complication rate compared to patients receiving autologous transplantation [3].

Source: Contemporary Clinical Trials - June 28, 2020 Category: Radiology Authors: Zev M. Nakamura, Allison M. Deal, Donald L. Rosenstein, Laura J. Quillen, Stephanie A. Chien, William A. Wood, Thomas C. Shea, Eliza M. Park Source Type: research